• IDEAYA Biosciences enrolled the first patient in a Phase 1 trial of IDE892 combined with MAT2A inhibitor IDE397 in MTAP-deleted solid tumors.
• The study targets pancreatic cancer and non-small cell lung cancer, where MTAP deletion is estimated at up to 40% and about 15%, respectively.
• No clinical results have been presented; IDE892 remains in Phase 1 dose escalation with expansion planned for Q3 2026.
• Preclinical work showed the IDE892-IDE397 combination produced strong anti-tumor activity, including durable responses, at doses below monotherapy requirements.
• IDEAYA also entered a clinical collaboration with Roche to test IDE892 with Roche’s Phase 1 pan-RAS inhibitor RG6505 in MTAP-deleted pancreatic cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEAYA Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202606150600PR_NEWS_USPR_____SF83018) on June 15, 2026, and is solely responsible for the information contained therein.